Comprehensive genomic analysis ofmolecular residual disease based on circulating tumour DNA in postoperative patients with colorectal cancer

Qingqi Hong; Jingtao Zhu; Hexin Lin; Yinan Chen; Haoyu Bai; Linghua Yan; Li Xiao; Jun You

doi:10.1002/ctm2.70041

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (10) : e70041 DOI: 10.1002/ctm2.70041

LETTER TO THE JOURNAL

Comprehensive genomic analysis ofmolecular residual disease based on circulating tumour DNA in postoperative patients with colorectal cancer

Author information +

History +

PDF

Cite this article

Download citation ▾

Qingqi Hong, Jingtao Zhu, Hexin Lin, Yinan Chen, Haoyu Bai, Linghua Yan, Li Xiao, Jun You. Comprehensive genomic analysis ofmolecular residual disease based on circulating tumour DNA in postoperative patients with colorectal cancer. Clinical and Translational Medicine, 2024, 14(10): e70041 DOI:10.1002/ctm2.70041

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[2]	Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(3): 329-359.

[3]	Yoshino T, Argiles G, Oki E, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann Oncol. 2021; 32(12): 1496-1510.

[4]	Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023; 29(1): 127-134.

[5]	Mo S, Ye L, Wang D, et al. Early detection of molecular residual disease and risk stratification for stage I to III colorectal cancer via circulating tumor DNA methylation. JAMA Oncol. 2023; 9(6): 770-778.

[6]	Chen G, Peng J, Xiao Q, et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. J Hematol Oncol. 2021; 14(1): 80.

[7]	Tarazona N, Gimeno-Valiente F, Gambardella V, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 2019; 30(11): 1804-1812.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.